The mammalian target of rapamycin (mTOR), which is a master regulator of cellular catabolism and anabolism, plays an important role in tumourigenesis and progression. In this study, we report the chemopreventive effect of the dietary compound ampelopsin (AMP) on breast carcinogenesis in vivo and in vitro, which acts by inhibiting the mTOR signalling pathway. Our study indicates that AMP treatment effectively suppresses 1-methyl-
Introduction
Breast cancer is the leading cause of cancer death among women in Europe and North America (1) . The National Cancer Institute has recognized that prevention is a critical component in minimizing the number of individuals who are afflicted with breast cancer (2). The mammalian target of rapamycin (mTOR) is an important component of the phosphatidylinositol 3-kinase (PI3K)/Akt signalling pathway that is frequently overactivated in various cancers, particularly in breast carcinogenesis and metastasis (3, 4) . The PI3K/Akt/mTOR signalling pathway acts as a key integration point between the extrinsic and intrinsic cellular environments (5, 6) , regulates a broad spectrum of cellular processes and is one of the major signalling pathways in tumourigenesis and development (7, 8) . The mTOR protein is a highly conserved 289 kDa protein serine/threonine kinase, and 95% of its amino acid composition is conserved from yeast to human (9) . mTOR functions downstream of the PI3K/Akt pathway and positively regulates the phosphorylation of ribosomal p70-S6 kinase (S6K70), ribosomal protein S6 (rpS6), eukaryotic translation initiation factor 4B and eukaryotic translation initiation factor 4E-binding protein (4EBP)1 to control protein translation (10, 11) . Recent studies suggest that targeting the mTOR signalling pathway may be an effective strategy for chemoprevention and cancer treatment (12, 13) . The results from several studies support the hypothesis that mTOR acts as a master switch of cellular catabolism and anabolism and thereby determines whether cells, particularly tumour cells, grow, proliferate and migrate (14, 15) . Currently, mTOR has emerged as one of the most significant intracellular signalling enzymes that regulate cell growth, survival and autophagy in breast cancer progression (16, 17) . Indeed, mTOR inhibitors have entered preclinical studies and clinical trials for various human cancers (18) . The mTOR signalling pathway therefore represents an attractive and promising target for preventive and therapeutic intervention. Therefore, isolating, selecting and developing inhibitors of mTOR signalling, especially from natural products, has become a widely investigated area of research.
Epidemiologic studies and systematic analyses suggest that diets rich in fruits, vegetables and tea are associated with a reduced risk of cancer, particularly cancers of epithelial origin, such as those of the mouth, colon, rectum, lung and breast (19, 20) . Dietary flavonoids, a group of polyphenolic compounds, have been identified as potential cancer-preventive components of plant food. Bioactive components in botanicals and herbal medicines may provide effective and safe candidates for the chemoprevention of cancer (21, 22) . Ampelopsin [AMP, (3, 5, 7 ,3′4′5′-hexahydroxyl 2,3 dihydrogen flavonol)], which is also referred to as dihydromyricetin, is one of the most common dietary flavonoids isolated from the tender stem and leaves of the plant species Ampelopsis grossedentata (Hand-Mazz) W.T. Wang. This species is widely distributed and consumed as a type of tea in Southern China and is also used to treat the common cold and tinea corporis. More than 27% of the AMP in these plants resides in the tender stem and leaves, and >40% is found in the cataphyll. AMP is reported to possess some important pharmacological activities, such as anti-inflammation, cough relief and hepatoprotection (23, 24) . Moreover, recent studies showed that AMP possesses certain anti-cancer activities that include inhibiting the growth and metastasis of prostate cancer and melanoma cells (25) . However, it is unclear whether AMP possesses effective chemopreventive activities against mammary carcinogenesis. In the present study, we evaluated the chemopreventive effect of AMP on breast carcinogenesis in vivo and in vitro and investigated the inhibitory effect and mechanism of AMP on the mTOR signalling pathway.
Materials and methods
Chemicals and reagents AMP was purchased from Mansite Bio-technology Co (Chengdu, China); DMEM/F12 medium and fetal bovine serum were purchased from HyClone (Beijing, China); Trizol reagent, horse serum, gentamicin, insulin, Lipofectamine 2000, Opti-Mem were purchased from Invitrogen (Carlsbad, CA); Epidermal growth factor (EGF) was purchased from PeproTech (Rocky Hill, NJ); K-LISA mTOR activity assay kit was purchased from Calbiochem (San Diego, CA); PathScan Phospho-Akt ELISA assay kit and all antibodies Abbreviations: 4EBP, eukaryotic translation initiationfactor 4E-binding protein; AMP, ampelopsin; B[a]P, benzo[a]pyrene; CM, complete medium; ER, estrogen receptor; HPLC, high-performance liquid chromatography; i.g., intragastrically; MNU, 1-methyl-1-nitrosourea; mTOR, mammalian target of rapamycin; mTORC, mTOR complexes; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; PBS, phosphate-buffered saline; PI3K, phosphatidylinositol-3-kinase; raptor, regulatory-associated protein of mammalian target of rapamycin; rictor, rapamycin-insensitive companion of mammalian target of rapamycin; rpS6, ribosomal protein S6; S6K70, ribosomal p70-S6 kinase. † These authors contributed equally to this work.
were purchased from Cell Signaling Technology (Danvers, MA). 
HPLC analysis of AMP in rats
Twelve female Sprague-Dawley rats were acclimatized to an AIN-93G diet for 3 days and randomly divided into two groups: control (n = 3) and AMP treatment group (n = 9). The rats in the AMP treatment group were intragastrically (i.g.) fed 100 mg/kg AMP, and the rats in the control group were i.g. fed the vehicle alone (normal saline). After treatment for 0.5, 1.0 and 2.0 h, three rats in each AMP treatment group were killed, and the rats in the control group were killed at 1.0 h. The plasma of the rats were collected and analysed by high-performance liquid chromatography (HPLC). The plasma sample (1.0 ml) was added with 5 μl β-glucuronidase (≥2000 units/ml), 5 μl sulfatase (≥8500 units/ml) and 1.5 ml sodium acetate solution (0.2 M), and then incubated in water for 30 min at 37°C. The mixed solution was added with 5.0 ml ethyl acetate (0.2 M), and centrifuged (3000 r.p.m.) for 10 min at 4°C. The supernatant solution was dried under reduced pressure for 5 h at 40 ˚C. The residue was dissolved with methanol and treated with 0.45 μm membrane filtration, and then analysed by HPLC. HPLC analyses were carried out on a Waters 1525 series liquid chromatography system equipped with a dual λ absorbance detector. The analyses were performed with a Hyper 0DS2 C18 column (4.6 mm × 50 mm, 1.8 μm) with 0.5% ethanoic acid (A) and methanol (B) as the mobile phase. Elution started at 15% (B), increasing to 67% within 40 min at a flow rate of 1.0 ml/min. AMP was quantified based on the peak area of the respective standard curves measured at 290 nm. Typically, 10 μl was injected for the analyses.
Experimental model of carcinogenesis in rats
The rats were acclimatised to an AIN-93G diet for 3 days and randomly divided into four groups: normal, control, low-dosage AMP administration and highdosage AMP administration groups. The rats in the low-and high-dosage AMP administration groups were i.g. fed 50 and 100 mg/kg/day AMP, respectively, and the rats in the normal and control groups were orally fed the vehicle alone (normal saline). One week later, all of the rats with the exception of those in the normal group were given a single intraperitoneal injection of MNU (50 mg/ kg), which was dissolved in physiological saline (10 mg/ml) containing 0.05% acetic acid and used within 30 min after preparation. The rats in normal group were injected with an equal volume of physiological saline. During the experiments, the rats were weighed twice per week and monitored once per day for mammary tumour development throughout the study and at the time of killing.
Effect of AMP on xenografted MDA-MB-231 cells in athymic mice
Female immunodeficient BALB/c nude mice were randomized and then implanted with MDA-MB-231 cells at a density of 2 × 10 6 cells/ml subcutaneously into the right axilla. Seventy-two hours after implantation, the mice were i.g. orally fed AMP (100 mg/kg/day; n = 6) or vehicle alone (normal saline; n = 6). The tumours were measured once every 4 days during the treatment period of 28 days, and the tumour volumes (Vt) [(L × W 2 )/2] were calculated from calliper measurements.
Chronic cellular breast carcinogenesis
Human breast epithelial MCF-10A cells were maintained in complete medium (CM) (DMEM/F12 medium supplemented with mitogenic additives, including 100 ng/ml cholera enterotoxin, 10 μg/ml insulin, 0.5 μg/ml hydrocortisol, 20 ng/ml epidermal growth factor, and 5% horse serum) in a humidified atmosphere of 5% CO 2 /95% air at 37°C. The cellular breast carcinogenesis model was processed as reported previously (26) . Briefly, MCF10A cells were treated with NNK and B[a]P (each at 100 pmol/l and with different concentrations of AMP (0, 10, 25 and 50 μM); the cultures were subcultured every 3 days. The cancer-associated properties of the treated cells were evaluated using the following assays. Reduced dependence on growth factors assay: 3 × 10 3 cells were seeded in low-mitogen medium, in which the total serum and mitogenic additives were reduced to 2% of the respective concentrations formulated in the CM, and the growing colonies that reached 0.5 mm in diameter within 10 days were counted. Anchorage-independent cell growth (AIG) assay: The base layer consisted of 2% low-melting agarose in CM, and soft agar consisting of 0.4% low-melting agarose in a mixture (1:1) of CM with 3-day conditioned medium prepared from MCF10A cultures was mixed with 5 × 10 3 cells and plated on top of the base layer in 60-mm diameter culture dishes; the growing colonies that reached 0.1 mm in diameter within 20 days were counted. Scratch/wound healing assay: Cells were seeded on 6 cm dishes and grown to confluence, and the cell monolayer was scraped with a sterile cell scraper to create a cell-free zone to produce wounded cultures; the wound healing areas were examined after 12 and 24 h by subtracting the area that had not healed from the total area of the initial wound.
Cell viability assay
The human breast cancer cell lines MCF-7 and MDA-MB-231 were grown in DMEM/F12 medium supplemented with 10% fetal bovine serum. The cells were plated in 24-well plates at a density of 10 5 cells per well overnight and treated with different concentrations of AMP (0, 10, 25 and 50 μM) for 48 h. At the end of the treatment, 40 μl of MTT (5 mg/ml) was added to each well, and the cells were cultured for another 4 h. The formazan crystals were dissolved in dimethylsulfoxide, and the absorbance was measured at 490 nm using a BioRad automatic EIA analyser.
Cell line authentication
Cell lines used in this study including human breast epithelial cell MCF10A, human breast cancer cell MCF-7 and MDA-MB-231, were all purchased from Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China) 22 May 2013. All cell lines have been tested and authenticated by DNA (short tandem repeat genotyping) profiling. The last test was performed in 12 March 2013.
mTOR kinase assay and p-Akt ELISA
The activities of mTOR and p-Akt (S473) were measured with a colorimetric K-LISA mTOR activity assay kit and a PathScan Phospho-Akt (S473) ELISA kit, respectively. Briefly, 10 7 cells were washed twice with Tris-buffered saline, and the cell lysates were prepared by the addition of 1 ml of lysis buffer (50 mM Tris HCl, pH 7.4, 100 mM NaCl, 50 mM β-glycerophosphate, 10% glycerol (wt/vol), 1% Tween®-20 detergent (wt/vol), 1 mM EDTA, 20 nM microcystin-LR, 25 mM NaF, and a cocktail of protease inhibitors). For the mTOR activity assay, the mTOR proteins in the cells were immunoprecipitated with mTOR antibody and protein A/G-agarose. The resulting immunocomplex and adenosine triphosphate were added to S6K70-coated wells. After the phosphorylation of S6K70 at T389 by the active mTOR in the sample, the phosphorylated substrate can be detected with anti-S6K70-T389 antibody. The mTOR activity can be measured in terms of its absorbance using a microplate reader. For the mTOR inhibitor testing, 50 μl of mTOR standard (provided by the kit) was incubated with different concentrations of AMP (0, 10, 25 and 50 μM) on ice for 20 min, and the mixtures were then transferred to the S6K70-coated wells. The remaining steps of the protocol are the same as those mentioned above. For the p-Akt assay, the p-Akt(S473) proteins in the cell lysate were captured by the corresponding antibody, which was coated in the microplate. After the addition of the horseradish peroxidase-linked secondary antibody and chemiluminescent substrate, the magnitude of the light emission, which is proportional to the quantity of p-Akt(S473) protein, was measured.
Western blot analysis
Cell lysates were prepared using radioimmunoprecipitation assay buffer (25 mM Tris-HCl, pH 7.6, 150 mM NaCl, 1% NP40, 1% sodium deoxycholate, and 0.1% sodium dodecyl sulfate) supplemented with protease and phosphatase inhibitors. Equal amounts of cellular proteins were resolved by electrophoresis in 10 or 12% sodium dodecyl sulfate-polyacrylamide gels for western immunoblotting with specific antibodies. The antigen-antibody complexes on the filters were detected by chemiluminescence.
Docking study
The blind docking of AMP to the mTOR target was performed with Autodock4 by setting grid sizes that included the entire mTOR molecule. The receptor site was prepared with Sybyl (Tripos, St Louis, MO) using the NMR structure 2NPU model 1 from the Protein Data Bank (www.pdb.org). The grid size for the docking site was expanded to include the entire mTOR molecule, and AMP was docked.
Immunoprecipitation
Treated cells were lysed in ice-cold lysis buffer (40 mM HEPES, pH 7.4, 2 mM EDTA, 10 mM β-glycerophosphate, 0.3% (wt/vol) CHAPS and protease
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inhibitors]. The soluble fractions of the cell lysates were isolated by centrifugation at 13 000g for 10 min. The lysate was precleared by incubation with 20 μl of protein A/G-agarose and 1 μg of rabbit IgG for 1 h. For immunoprecipitation, an antibody against mTOR was added to the lysates, and the lysates were incubated with rotation for 2 h at 4°C. Twenty millilitres of a 50% slurry of protein G-sepharose was then added, and the lysates were incubated for an additional 1 h. The immunoprecipitates were washed three times with lysis buffer. The immunoprecipitated proteins were denatured by the addition of 20 ml of sample buffer and boiling for 5 min, resolved by 8-16% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and analysed by western blot.
Immunofluorescence
MDA-MB-231 cells were cultured in six-well chambered slides and treated with different concentrations of AMP (0, 10, 25 and 50 μM) for 24 h. The slides were then rinsed with PBS, and the cells were fixed with 2% paraformaldehyde and permeabilized in methanol. After washing with PBS, the slides were blocked with 2% donkey serum for 0.5 h and incubated with an antibody against p-4EBP1(S65) (dilution 1:200) in 5% donkey serum at 4°C overnight. Negative controls were performed by omitting the primary antibody. The slides were rinsed and incubated with secondary antibodies at 37°C for 1.0 h. The Nuclei were counterstained with 4′,6-diamidino-2-phenylindole (1:1500), and the slides were immediately analysed through laser confocal scanning microscopy.
Immunohistochemistry
Tissue sections (4 μm thick) were placed onto treated slides, heat fixed, deparaffinized, rehydrated, boiled in citrate buffer for antigen retrieval and treated with 3% hydrogen peroxide to block endogenous peroxidase activities. After washing with PBS, the slides were blocked with 2% donkey serum for 0.5 h and then incubated with an antibody against p-mTOR(S2448) (dilution 1:250) or an antibody against p-Akt(T308) (dilution 1:200) at 4°C overnight. Negative controls were performed by omitting the primary antibody. The secondary biotinylated antibody was then applied, and the signal was developed using a modified avidin-biotin complex immunoperoxidase staining procedure. Counterstaining was performed with Trypan blue or Harris haematoxylin. The positive cells were quantified per highpower field, and 10 high-power field were averaged for each case. At least three sections were analysed for each sample.
Statistical analysis
The results are presented as the means ± SD from at least three independent experiments. The tumour incidences were compared using the χ 2 test. The other data were analysed by one-way analysis of variance followed by Tukey's test for multiple comparisons. The difference significance was set at P < 0.05.
Results

Chemopreventive effects of AMP against breast carcinogenesis in rats
We first detected the bioavailability of AMP in rats by HPLC analysis. Our study showed that the serum concentration of AMP in rats 0.5, 1.0 and 2.0 h after the oral administration of AMP (100 mg/kg, i.g.) was 1.3 ± 0.8, 11.4 ± 2.7 and 7.6 ± 1.7 μg/ml, respectively.
Using the classical experimental model of MNU-induced breast carcinogenesis in rats, we then evaluated the chemopreventive effects of AMP in vivo. As shown in Table I , the tumour incidence in the AMP administration group (100 mg/kg) was significantly lower than that observed in the control. The cancer incidence was decreased by 37.4%, indicating that the oral administration of AMP can effectively suppress MNU-induced mammal breast carcinogenesis. The histopathological sections of breast tissue and tumours showed evidence of carcinogenesis ( Figure 1A) . No evidence of adverse effects was observed in the rats that were administered AMP orally, and these animals grew at the same rate as the controls.
AMP suppresses environmental carcinogen-induced cellular carcinogenesis
Using cancer-associated properties as the target endpoints, we assessed the chemopreventive effects of AMP on NNK-and B[a]P-induced chronic breast carcinogenesis in vitro. As shown in Figure 2A and B, a lack of growth factors or adhesion to extracellular matrixes caused the growth arrest of MCF10A cells. MCF10A cells treated with carcinogens (CarT) for 30 days showed aberrantly increased cell survival adapted to reduced dependence on growth factors and anchorageindependent cell growth, indicating cellular tumourigenic transformation. Compared with CarT, cells co-treated with carcinogens and AMP (C-AMP) for 30 days exhibited a significantly lower acquisition of reduced dependence on growth factors and anchorage-independent cell growth. Similarly, CarT cells required significantly increased mobility and proliferation to heal the wound, which may be inhibited by AMP cotreatment ( Figure 2C ). These data suggest that AMP can significantly suppress carcinogen-induced cellular carcinogenic transformation.
AMP inhibits the growth of breast cancer cells in vitro and in vivo
The cell viability assay ( Figure 1C) showed that AMP significantly decreases the viability of breast cancer cells MCF-7 and MDA-MB-231 in a dose-dependent manner but shows no apparent cytotoxicity on MCF10A cells. We then evaluated the anti-tumour activity of AMP in athymic mice with xenografts of MDA-MB-231 cells. The results ( Figure 1B and D) showed that the tumour volume in the AMP-treated mice was significantly smaller than that in the control at the same measurement day. These results indicate that AMP can effectively inhibit the growth of breast cancer cells in vitro and in vivo.
AMP inhibits the activity of mTOR kinase in vitro and in vivo
We measured the activity of mTOR kinase, and the results ( Figure 3A) showed that the activity of mTOR kinase in CarT cells is significantly increased in a time-dependent manner. Compared with CarT, the mTOR activity in C-AMP cells is significantly lower, suggesting that AMP co-treatment can abrogate the carcinogen-induced promotion of mTOR activity. In addition, our study showed that AMP treatment can effectively suppress mTOR activity in breast cancer MDA-MB-231 cells ( Figure 3B) .
We then performed western blots of the proteins correlated with the activity of mTOR. The results ( Figure 3C ) showed that the phosphorylations of mTOR at S2448 and S2481 in CarT cells are increased Values are means ± S.D. The tumour incidence in MNU plus 100 mg/kg AMP treatment group were significantly lower than that in MNU only treatment group, indicating that oral administration of AMP (100 mg/kg/day) can effectively suppress MNU-induced mammal breast carcinogenesis. *P < 0.05 compared with MNU only treatment group.
H.Chang et al. in a time-dependent manner, confirming the carcinogen-induced activation of mTOR. AMP co-treatment can potently suppress the activation of mTOR in cellular carcinogenesis. Accordingly, the results ( Figure 3D) showed that AMP treatment also suppresses mTOR activation in MDA-MB-231 cells. Additionally, the immunohistochemistry detections of p-mTOR(S2448) in breast tissues and tumours showed that AMP administration can significantly inhibit the activation of mTOR in MNU-treated rats ( Figure 4A ) and in xenografted breast tumours ( Figure 4B) in vivo.
We then performed mTOR inhibitor testing of AMP, and the data ( Figure 3E) showed that AMP is an effective mTOR inhibitor that can significantly inhibit mTOR activity in a dose-dependent manner. We also performed blind docking of AMP to the mTOR target using Autodock4 by setting grid sizes that included the entire mTOR molecule. The results ( Figure 3F ) indicated that AMP binds to one site on the mTOR target in two ways with binding energies of −7.1 and −7.0 kcal/mol, respectively.
AMP represses the activation of Akt in carcinogenesis and in cancer cells
Given the intimate cross-talk between mTOR and Akt, we investigated the effects of AMP on Akt activation. Western blots ( Figure 5A ) showed that the levels of total Akt and p-Akt(T308, S473), particularly the ratio of p-Akt to Akt, in CarT cells was increased in a time-dependent manner, indicating that Akt is activated in carcinogenesis. The p-Akt enzyme-linked immunosorbent assay results ( Figure 5C ) confirmed the significant promotion of Akt activity in CarT cells. The results showed that AMP co-treatment can effectively suppress Akt activation in cellular carcinogenesis. AMP treatment also significantly decreased Akt activity in MDA-MB-231 cells in a dose-dependent manner ( Figure 5B  and D) . Furthermore, the immunohistochemistry detections of p-Akt(T308) in MNU-treated rats ( Figure 4C ) and in xenografted tumours ( Figure 4D) showed that AMP administration inhibits the activation of Akt in vivo.
AMP suppresses the formation of mTORC1/2 and downstream targets of mTOR
We performed immunoprecipitation experiments combined with a western blot assay to determine the effects of AMP on the formation of mTOR complexes (mTORC)1/2. First, the western blot results ( Figure 6A and B) showed no apparent difference in the levels of mTOR, regulatory-associated protein of mammalian target of rapamycin (raptor), rapamycin-insensitive companion of mammalian target of rapamycin (rictor) and mLST8 between 30-d CarT and 30-d C-AMP cells. Similarly, AMP treatment showed no effects on the expression of these proteins in MDA-MB-231 cells. Further study (Figure 6C and D) showed that significantly lower amounts of raptor and rictor but not of mLST8 were isolated with an mTOR antibody in 30-d C-AMP and AMP-treated MDA-MB-231 cells compared with CarT and the control, respectively. These data indicate that AMP disrupts mTORC1/2 formation by dissociating raptor/rictor from mTOR instead of decreasing protein expression. Moreover, we assessed the effects of AMP on the downstream targets of mTOR. Our study showed that the levels of p-S6K70(T389 and T421), p-rpS6(S235/236), p-eIF4B(S422) and p-4EBP1(S65) were all significantly decreased in 30-d C-AMP ( Figure 6E ) and AMP-treated MDA-MB-231 cells ( Figure 6F and G) compared with CarT and the control, respectively. These data indicate the substantial suppressive effects of AMP on the downstream targets of mTOR in carcinogenesis and in cancer cells.
Discussion
Previous studies have suggested that more than 70% of sporadic breast cancers are attributable to long-term exposure to environmental factors, particularly various chemical carcinogens, and this chronic pathological process involves accumulated genetic and epigenetic alterations to induce the progressive carcinogenesis of breast cells from the noncancerous to the precancerous and cancerous stages (27, 28) . In the present study, we used the chemical carcinogen MNU to induce breast tumours in rats, and we adopted a cellular model to mimic chronic breast cell carcinogenesis that occurs with accumulated exposures to low doses of environmental carcinogens. Our study showed that the dietary flavonoid compound AMP, which is abundant in Rattan tea, effectively suppresses breast carcinogenesis in vivo and in vitro, indicating that AMP is an effective and promising natural chemopreventive agent against breast cancer. Our findings will likely provide useful insight and evidence that can be used by registered dietitians and other healthcare professionals when discussing diet and cancer prevention with patients. However, the cancer-preventive effects of AMP were only shown in animal and cell culture studies. Because human clinical trials examining the chemopreventive potential of AMP have not been conducted, more studies are warranted to confirm the results. The mTOR pathway has emerged as an important cancer preventive and therapeutic target. Several mTOR inhibitors have been approved by the US FDA for various clinical indications. Rapamycin was the first of its class and the prototype for the newer generation of mTOR inhibitors. For patients with breast cancer, particularly endocrineresistant breast cancer patients, mTOR inhibitors offer a new hope and promise (29, 30) . Endocrine therapy is indispensable in the treatment of patients with metastatic estrogen receptor (ER)-positive breast cancer and can prevent cancer progression for extended periods of time with low toxicity and cost. Despite the benefits of endocrine therapy, however, therapeutic resistance remains a major obstacle. Acquired resistance to endocrine therapy, especially aromatase inhibitor therapy, continues to represent the key limitation in the treatment of patients with metastatic breast cancer (31, 32) . Preclinical and clinical studies have revealed that the molecular cross-talk between ER and other critical survival and growth signalling pathways in breast cancer contributes to endocrine resistance. One of the most critical signalling pathways that may emerge after prolonged estrogen deprivation in ER-positive breast cancer is the PI3K/AKT/mTOR survival pathway (33, 34) . Clinical evidence emphasizes that mTOR inhibitors can restore sensitivity to endocrine therapy and may serve as a target to reverse resistance; in addition, aromatase inhibitor plus an mTOR inhibitor is effective for the treatment of heavily pretreated metastatic ER-positive breast cancer (35, 36) .
Similar to endocrine therapy, cancer cells can also develop resistance to mTOR inhibitors through a negative feedback loop in which mTOR inhibition leads to Akt activation (37, 38) . Indeed, mTOR and Akt exhibit an intimate cross-talk for mutual promotion. On the one hand, mTOR functions downstream of the PI3K/Akt pathway and is phosphorylated in response to stimuli that activate Akt. On the other hand, Akt is also a direct target of mTORC2, which contributes to its activation. Therefore, it is important for cancer prevention and therapy to dually inhibit the mTOR pathway and Akt activation. Rapalogs specifically inhibit mTORC1 and hardly affect mTORC2, which leads to Akt activation and drug resistance. Our findings revealed that AMP can repress the aberrant expression and activation of Akt, which may contribute to the suppression of the mTOR signalling pathway in breast cancer and in carcinogenesis. In addition, AMP also inhibits the formation of mTORC2, negating one of the disadvantages of rapalogs, which is the negative feedback activation of Akt. Additionally, their potential toxicities, such as pneumonitis, mucositis and metabolic changes, limit the benefits of mTOR inhibitors in cancer therapy. Therefore, our findings suggest that AMP, a natural dietary compound, may serve as a useful supplement for improving the efficacy of mTOR inhibitors in breast cancer treatment.
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